Recursion Pharmaceuticals (NASDAQ:RXRX) PT Lowered to $15.00 at Needham & Company LLC
Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its price target cut by Needham & Company LLC from $17.00 to $15.00 in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a buy rating on the stock. Separately, KeyCorp upped their price objective on shares of Recursion Pharmaceuticals from $12.00 to […]
More Stories
House Speaker Details GOP Plan to Raise Debt Ceiling in Reconciliation Bill
By Tom Ozimek House Speaker Mike Johnson (R-La.) said on Jan. 7 that congressional Republicans plan to raise the nation’s...
Borders & Southern Petroleum (LON:BOR) Shares Down 6.3% – Here’s Why
Borders & Southern Petroleum plc (LON:BOR – Get Free Report) was down 6.3% on Tuesday . The stock traded as...
Sugary Drinks Linked to Millions of New Diabetes and Heart Disease Cases
By Rachel Ann T. Melegrito Sugary drinks are a major contributor to chronic health issues. A new study from Tufts...
Thousands of Californians Flee Massive Palisades Fire Fueled by Strong Winds
By Jill McLaughlin A fast-moving wildfire erupted in the Southern California coastal city of Pacific Palisades, about 20 miles west...
FAT Brands Inc. Announces Income Tax Treatment of Dividends and Adjustments
On January 7, 2025, FAT Brands Inc. (NASDAQ: FAT) submitted a Form 8-K filing with the Securities and Exchange Commission...
Getty Images (NYSE: GETY) Announces Merger Agreement with Shutterstock (NYSE: SSTK) to Form Premier Visual Content Company
Seattle-based Getty Images Holdings, Inc. has officially entered into a definitive agreement to merge with Shutterstock. This transformative merger, with...